CytRx
Corporation CYTR announces further positive
clinical data from a multi-site global Phase 2b study comparing the
Company's aldoxorubicin as a first-line treatment for advanced soft
tissue sarcomas (STS) versus the widely used chemotherapeutic agent
doxorubicin. The data is contained in a poster presented today at the 18th
Annual Connective Tissue Oncology Society Meeting at the Sheraton New
York Times Square Hotel and includes additional information captured
between September 27 and October 16, 2013. The study is still ongoing,
and as of October 16, 2013, 47 patients remained active in the clinical
trial (36 on aldoxorubicin and 11 on doxorubicin). CytRx expects to
report top-line progression-free
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in